Akeso cancer drug ivonescimab shows strong phase three efficacy in lung cancer.

Chinese biotech Akeso reports better-than-expected phase three trial results for its lung cancer drug ivonescimab, which analysts say could become a backbone therapy in the $20 billion global non-small cell lung cancer market.